Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First in Human, Phase 1/1b Study of Single and Multiple Ascending Dosing Administration of NTX110253 in Healthy Participants and Participants With Stable Schizophrenia

NCT07344948 is registered in ClinicalTrials.gov with Neurosterix as lead sponsor.

NCT NCT07344948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07344948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First in Human, Phase 1/1b Study of Single and Multiple Ascending Dosing Administration of NTX110253 in Healthy Participants and Participants With Stable Schizophrenia
Lead sponsor
Neurosterix
Phase
Phase 1
Overall status
Recruiting
Start date
October 3, 2025
Completion date
May 31, 2026
Enrollment
73 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants, schizophrenia diagnosis